Renal transplantation offers the potential for improved quality and length of life to patients with end-stage renal disease; however, graft rejection and immunosuppression-related toxicities can hamper the effectiveness of this therapy. Seminal publications from 2010 have addressed these obstacles, and provide insight into new and innovative approaches to improve outcomes in renal transplant recipients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vincenti, F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 536–546 (2010).
Durrbach, A. et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENIFIT-EXT study). Am. J. Transplant. 10, 547–557 (2010).
Walsh, R. C. et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89, 277–284 (2010).
Sberro-Soussan, R. et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am. J. Transplant. 10, 681–686 (2010).
Salgo, R. et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)maglignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded controlled clinical trial. Am. J. Transplant. 10, 1385–1395 (2010).
Poommipanit, N. et al. Pancreas after living donor kidney versus simultaneous pancreas-kidney transplant: an analysis of the organ procurement transplant network/united network of organ sharing database. Transplantation 89, 277–284 (2010).
Stegall, M. D. et al. Terminal complement inhibition decreases early acute humoral rejection in sensitized renal transplant recipients [abstract 1]. Am. J.Transplant. 10, 39 (2010).
Robbins, W. R., Schmidt, W. K. & Lee, V. J. LIM-0705, an activator of specific ABC transporters, prevents and treats tacrolimus-induced hyperglycemia in the rat [abstract 148]. Am. J. Transplant. 10, 84 (2010).
Robbins, W. R. et al. LIM-0705 activates specific ABC transporters allowing efflux of tacrolimus out of rat kidney and pancreas that may help ameliorate toxicity [abstract 149]. Am. J. Transplant. 10, 84 (2010).
Robbins, W. R. et al. LIM-0705 an activator of specific ABC transporters, prevents and treats tacrolimus-induced renal tubular vacuolization in a rat model [abstract 150]. Am. J. Transplant. 10, 85 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author is on a Data Monitoring Committee for Bristol–Myers Squibb and StemCells Inc., and is a member of Genentech's Valcyte Regional Advisory Board.
Rights and permissions
About this article
Cite this article
Shapiro, R. Innovative approaches to improve outcomes in transplantation. Nat Rev Nephrol 7, 68–70 (2011). https://doi.org/10.1038/nrneph.2010.179
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.179